Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eplerenone Sandoz Inc., USA · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Eplerenone 50mg Tablets |
| 2 | ACTIVE_COMPARATOR | INSPRA 50mg Tablets |
| Name | Type | Description |
|---|---|---|
| Eplerenone 50 mg Tablets Sandoz Inc., USA | DRUG | - |
| Inspra 50 mg Tablets GD Searle LLC, USA | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Top 7 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, LY3971297 |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | QCZ484 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
Eplerenone Sandoz Inc., USA is a small molecule drug developed by Novartis AG (ticker NVS) for hypertension, a cardiovascular condition. It is also known as Eplerenone 50 mg Tablets Sandoz Inc., USA. The product is in Phase 1 development, with two completed Phase 1 bioavailability trials in healthy adult volunteers.
Eplerenone Sandoz Inc., USA is being developed for hypertension, a cardiovascular condition. The clinical program consists of two completed Phase 1 comparative bioavailability studies conducted in healthy adult volunteers under fed and fasting conditions, with a combined enrollment of 120 participants.
Eplerenone Sandoz Inc., USA targets NR3C2, also known as the mineralocorticoid receptor. It acts as an antagonist at this receptor. By blocking NR3C2, the drug opposes mineralocorticoid receptor signaling, which is the mechanism underlying its development for hypertension.
Eplerenone Sandoz Inc., USA is developed by Novartis AG, which trades under the ticker NVS. The drug is a small molecule product candidate being studied for hypertension within the cardiovascular therapeutic area.
Eplerenone Sandoz Inc., USA is in Phase 1 development. Both of its clinical trials are Phase 1 comparative bioavailability studies, and both are completed. No active trials are ongoing. The program enrolled 120 participants in total, and the studies were randomized and active controlled.
Eplerenone Sandoz Inc., USA has been studied in two completed Phase 1 trials: NCT00865618, a comparative bioavailability study of the 50 mg tablets under fed conditions, and NCT00865176, the same comparison under fasting conditions. Each trial enrolled 60 healthy adult volunteers of any sex, aged 18 years and older.